Ohana Vaccines delivers novel vaccines to combat prostate cancer. Ohana’s Pro-V vaccine is a therapeutic vaccine for patients with recurrent prostate cancer that effectively destroys expressing tumor cells while leaving normal cells unharmed. Ohana Vaccines has completed both Phase I and II clinical trials on a precursor of the Pro-V vaccine and demonstrated significant efficacy with negligible toxicity. Based on these positive results, Ohana is approved to perform combined Phase I/II trials. Ohana’s management team and advisory board is composed of highly experienced people in both science and business. Ohana is actively and continuously seeking business investors and industrial partners.

Venture Information
Stage: 
Pre-Clinical
Industry: 
Therapeutics & Drugs
Technology or Science Area: 
Cancer vaccine to cure recurring prostate cancer
Type of Product: 
Medical Vaccine
Funding Round: 
Angel
Company Information
Founders: 
David Lubaroff